ECE2017 Eposter Presentations: Reproductive Endocrinology Male Reproduction (26 abstracts)
How relevant are the complications associated with testosterone treatment in men with hypogonadism?
Ricardo Capitão 1 , Raquel Castro 2 , Cátia Ferrinho 1 , Francisco Santos 1 , Catarina Roque 1 , Carlos Bello 1 , João Sequeira 1 , Catarina Saraiva 1 & Carlos Vasconcelos 1
1Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; 2Centro Hospitalar Lisboa Norte, Lisboa, Portugal.
Introduction: Testosterone treatment in patients with hypogonadism has been associated with cardiovascular and prostatic complications.
Objective: To describe the evolution of analytical parameters associated to the complications of testosterone treatment in a male population with hypogonadism treated with testosterone. Methods A retrospective, longitudinal study in which the clinical data of male adults with hypogonadism under intramuscular testosterone therapy were analysed in 2 tertiary centres. The duration and doses of testosterone were recorded. Haematocrit (Hct), total cholesterol (TC), LDL cholesterol (c-LDL), total prostate-specific antigen (PSA) and total testosterone levels were assessed at the beginning and at the end of follow-up. Paired-t-test was used to compare means and the results are shown in mean and standard deviation.
Results: We analysed 128 patients, 35% primary and 65% secondary hypogonadism. The mean age was 49.6±17.3 years. The follow-up time was 2.6 years (0.6–9.4 years). The mean interval between injections was 4.4±2.3 weeks. The final testosterone was 392.0±112.7 ng/dl. The results are summarized in the table below: Treatment with testosterone resulted in increased Hct and PSA values, however only the Hct difference proved statistically significant. Spearman correlation test revealed a positive and statistically significant correlation between the increase of testosterone levels and the increase of Hct (r=0.21; P=0.03). No hospitalizations for cardiovascular events were reported.
| Hct (%) | TC (mg/dl) | C-LDL (mg/dl) | PSA (ng/ml) | |
| First measurement | 42.9±5.0 | 194.3±41.5 | 114.1±37.3 | 1.4±1.7 |
| Final measurement | 44.0±4.4 | 191.7±30.2 | 110.8±28.3 | 1.7±2.4 |
| Difference | 1.1±4.4 | −2.6±38.2 | −3.4±34.8 | 0.3±1.6 |
| P-values | 0.01 | 0.68 | 0.60 | 0.30 |
Discussion: The rise of Hct, although statistically significant, was low. The remaining parameters did not show statistically significant increases so testosterone therapy appears to be safe from a cardiovascular and prostatic perspective.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more